WaferGen Bio-systems, Inc. engages in the development, manufacture and sale of genomic technology solutions for single-cell analysis (SCA) and clinical research. SmartChip System The company’s SmartChip System provides a suite of gene expression and genome analysis technologies enabling both biomarker discovery and validation on a single platform with the sensitivity and accuracy of real-time polymerase chain reaction (PCR). Its software system also analyzes the high throughput data after the completion of the real-time PCR analysis. The content-ready SmartChip System is designed to accept samples out of the box, incorporating various of the necessary substrates and chemicals. The company’s SmartChip Panels are designed with evaporation control measures that allow for the use of nanoliter volumes, thermal cycling and temperature control. The company’s SmartChip System is an integrated instrument and software system capable of dispensing 100nl reactions into the 5,184-well SmartChip, thermal cycling, real-time detection and primary data analysis. SmartChip Single-Cell Isolation System The ICELL8 Single-Cell System could isolate various single cells and processes specific cells for analysis, including next generation sequencing (NGS). The system has demonstrated unbiased isolation, regardless of cell size, of approximately 1,800 single cells, ranging from 5-100 micrometers in size on a single chip, including single cells from solid tumors, brain cells, pulmonary airway cells, and multiple cell lines. ICELL8 comprises the SmartChip and MultiSample Nano-Dispenser, which have been modified for single cell isolation and analysis. The ICELL8 Chip technology is developed for single-cell isolation through individual nanowell barcoding for cell registration and reagent optimization to improve cell separation and viability. In addition, the CellSelect software images cells, identifies wells that contain a single cell and then directs dispensing of reagents only to wells that contain single cells. The company collaborates with the Broad Institute to obtain proof of concept for cell isolation processes and RNA-Seq analysis that it uses to develop the products designed for SCA. In mid-2015, the company signed on four early access partners for its SmartChip SCA products - Karolinska Institutet, National Jewish Hospital, Genentech and MD Anderson Cancer Center. SmartChip Target Enrichment (TE) System The SmartChip TE and Seq-Ready TE Systems use the SmartChip consumable for amplifying the targets of interest through PCR. By separating PCR reactions into individual wells, its SmartChip TE System offers a controlled chemo-enzymatic process that might ultimately translate into higher quality sequencing results. The company offers multiple consumable formats of different densities (number of nano-wells) so that, depending on the number of targets required for a particular study, samples could be dispensed over the whole chip in flexible configurations. This enables the system to enrich targets without cross-contamination with other samples and provides the flexibility to customize targets. Apollo 324 Library Preparation In January 2014, the company acquired from IntegenX Inc. (IntegenX) substantially all of the assets of its product line used in connection with developing, manufacturing, marketing and selling instruments and reagents relating to library preparation for NGS, including the Apollo 324 instrument and the PrepX reagents (the ‘Apollo Business’). The Apollo 324 System is a walk-away automation platform offering DNA, RNA-Seq, and ChIP-Seq library preparation kits for analysis on popular NGS platforms from Illumina, Inc. (GA, HiSeq and MiSeq); Thermo Fisher Scientific, Inc. (Ion Proton and Ion Torrent PGM); and the Roche family of companies (GS Junior and GS FLX+). The PrepX automation protocols and reagent kits enable the set-up of a run with approximately 15 minutes of hands-on time. The user could return in about 90 minutes for sequencer-ready DNA or ChIP-Seq libraries, or about 5 hours for RNA-seq libraries. The system offers the flexibility to start a run with a single library without wasting reagents. Research and Development The company’s research and development expenses were approximately $9.28 million for the year ended December 31, 2015. Intellectual Property The company has 6 patents issued and 12 pending in the U.S. with respect to its SmartChip products and technologies, and various pending SmartChip-related patent applications worldwide. Competition The company’s competitors include 10X Genomics, Inc.; Agilent Technologies, Inc.; Fluidigm Corporation; Illumina, Inc.; PerkinElmer, Inc.; and Thermo Fisher Scientific, Inc. History WaferGen Bio-systems, Inc. was founded in 2002.
wafergen bio-systems inc
7400 Paseo Padre Parkway
Fremont, CA 94555
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for WGBS.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact WAFERGEN BIO-SYSTEMS INC, please visit www.wafergen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.